ArticleBMJ open2025

GABRINOX-2 protocol: a French, prospective, multicentre, randomised phase II trial evaluating gemcitabine/nab-paclitaxel followed by FOLFIRINOX versus FOLFIRINOX alone as first-line treatment for metastatic pancreatic cancer.

Fabienne Portales et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.